BackProcessa Pharmaceuticals Overview

Processa Pharmaceuticals Other Current Assets

Latest other current assets for PCSA: $250K.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$247363.00
71.26% YoYΔ $-613451.00 vs prior year quarter

Peer average

Loading

Processa Pharmaceuticals Other Current Assets History

Loading

Processa Pharmaceuticals vs. peers: Other Current Assets Comparison

Loading

Processa Pharmaceuticals Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Processa Pharmaceuticals (PCSA) FAQ

The latest other current assets for PCSA is $250K as of March 2026. That compares with $860K in the prior-year period — down 71.3% year over year. Investors often review this figure alongside Processa Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, PCSA's other current assets moved from $860K to $250K — a 71.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Processa Pharmaceuticals's operating scale or balance-sheet position.

A other current assets figure of $250K for PCSA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting PCSA's other current assets ($250K), review year-over-year change from $860K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Processa Pharmaceuticals's other current assets against similar Industrials names. You can also browse sector and industry screens on Stockcircle for a broader set of Industrials companies and their key multiples and fundamentals.